Telix Pharmaceuticals Limited (TLX)

Telix Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	664.23	484.69	342.57	108.81	5.52	4.02
Revenue Growth (YoY)	55.35%	41.49%	214.82%	1870.12%	37.33%	64.26%
Cost of Revenue	305.95	185.2	134.99	44.29	1.85	1.56
Gross Profit	358.28	299.49	207.58	64.52	3.67	2.46
Selling, General & Admin	168.71	128.18	84.72	59.2	34.16	18.88
Research & Development	153.75	120.45	87.62	55.06	24.82	17.81
Other Operating Expenses	7.72	0.18	-0.13	0.63	-	-
Operating Expenses	330.18	248.81	172.21	114.89	62.75	40.46
Operating Income	28.1	50.68	35.37	-50.37	-59.08	-38
Interest Expense	-10.64	-4.48	-0.53	-0.22	-0.12	-0.15
Interest & Investment Income	9.84	6.72	0.69	0	-	0.05
Currency Exchange Gain (Loss)	13.4	11.58	-0.66	-0.76	1.23	-3.04
Other Non Operating Income (Expenses)	-19.57	-18.37	-8.85	-4.33	10.25	9.34
EBT Excluding Unusual Items	21.14	46.12	26.02	-55.68	-47.71	-31.79
Merger & Restructuring Charges	-5.36	-5.06	-	-	-	-
Asset Writedown	0.5	0.48	-0.55	-	-	-
Other Unusual Items	-7.24	-6.85	-23.36	-11.36	-10.8	-5.19
Pretax Income	9.04	34.69	2.1	-67.03	-58.51	-36.98
Income Tax Expense	-1.8	3.8	-1.45	3.71	0.03	-2.35
Net Income	10.84	30.89	3.55	-70.74	-58.54	-34.63
Net Income to Common	10.84	30.89	3.55	-70.74	-58.54	-34.63
Net Income Growth	-66.76%	769.68%	-	-	-	-
Shares Outstanding (Basic)	254	331	319	311	282	257
Shares Outstanding (Diluted)	260	345	324	311	282	257
Shares Change (YoY)	-37.99%	6.64%	4.21%	10.08%	9.69%	10.21%
EPS (Basic)	0.04	0.09	0.01	-0.23	-0.21	-0.13
EPS (Diluted)	0.04	0.09	0.01	-0.23	-0.21	-0.14
EPS Growth	-45.24%	715.36%	-	-	-	-
Free Cash Flow	9.64	17.77	9.68	-48.26	-44.11	1.32
Free Cash Flow Per Share	0.04	0.05	0.03	-0.15	-0.16	0.01
Gross Margin	53.94%	61.79%	60.60%	59.29%	66.46%	61.17%
Operating Margin	4.23%	10.46%	10.32%	-46.29%	-1069.60%	-944.81%
Profit Margin	1.63%	6.37%	1.04%	-65.01%	-1059.90%	-861.06%
Free Cash Flow Margin	1.45%	3.67%	2.83%	-44.35%	-798.67%	32.84%
EBITDA	36.41	54.2	38.97	-47.3	-55.79	-34.67
EBITDA Margin	5.48%	11.18%	11.38%	-43.47%	-	-
D&A For EBITDA	8.31	3.52	3.6	3.07	3.29	3.33
EBIT	28.1	50.68	35.37	-50.37	-59.08	-38
EBIT Margin	4.23%	10.46%	10.32%	-46.29%	-	-
Effective Tax Rate	-	10.95%	-	-	-	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q